scholarly journals Chinese Herbal Medicine Ganoderma tsugae Displays Potential Anti-Cancer Efficacy on Metastatic Prostate Cancer Cells

2019 ◽  
Vol 20 (18) ◽  
pp. 4418 ◽  
Author(s):  
Wen-Chin Huang ◽  
Meng-Shiun Chang ◽  
Shih-Yin Huang ◽  
Ching-Ju Tsai ◽  
Pin-Hung Kuo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Growth ◽  
Cancer Progression ◽  
Metastatic Prostate Cancer ◽  
Xenograft Model ◽  
Ethanol Extract ◽  
Cancer Cell Growth ◽  
Medicine Quality

Resistance to the current therapies is the main clinical challenge in the treatment of lethal metastatic prostate cancer (mPCa). Developing novel therapeutic approaches with effective regimes and minimal side effects for this fatal disease remain a priority in prostate cancer study. In the present study, we demonstrated that a traditional Chinese medicine, quality-assured Ganoderma tsugae ethanol extract (GTEE), significantly suppressed cell growth and metastatic capability and caused cell cycle arrest through decreasing expression of cyclins in mPCa cells, PC-3 and DU145 cells. GTEE also induced caspase-dependent apoptosis in mPCa cells. We further showed the potent therapeutic efficacy of GTEE by inhibiting subcutaneous PC-3 tumor growth in a xenograft model. The in vitro and in vivo efficacies on mPCa cells were due to blockade of the PI3K/Akt and MAPK/ERK signaling pathways associated with cancer cell growth, survival and apoptosis. These preclinical data provide the molecular basis for a new potential therapeutic approach toward the treatment of lethal prostate cancer progression.

scholarly journals Inhibition of the Lysophosphatidylinositol Transporter ABCC1 Reduces Prostate Cancer Cell Growth and Sensitizes to Chemotherapy

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2022 ◽  
Author(s):  
Aikaterini Emmanouilidi ◽  
Ilaria Casari ◽  
Begum Gokcen Akkaya ◽  
Tania Maffucci ◽  
Luc Furic ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Growth ◽  
Cancer Cell ◽  
Cancer Progression ◽  
Prostate Cancer Cell ◽  
Cancer Cell Growth ◽  
Direct Role ◽  
In Vivo Models

Expression of ATP-binding cassette (ABC) transporters has long been implicated in cancer chemotherapy resistance. Increased expression of the ABCC subfamily transporters has been reported in prostate cancer, especially in androgen-resistant cases. ABCC transporters are known to efflux drugs but, recently, we have demonstrated that they can also have a more direct role in cancer progression. The pharmacological potential of targeting ABCC1, however, remained to be assessed. In this study, we investigated whether the blockade of ABCC1 affects prostate cancer cell proliferation using both in vitro and in vivo models. Our data demonstrate that pharmacological inhibition of ABCC1 reduced prostate cancer cell growth in vitro and potentiated the effects of Docetaxel in vitro and in mouse models of prostate cancer in vivo. Collectively, these data identify ABCC1 as a novel and promising target in prostate cancer therapy.

794: Valproic Acid Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo

2006 ◽  
Vol 175 (4S) ◽  
pp. 257-257
Author(s):  
Jennifer Sung ◽  
Qinghua Xia ◽  
Wasim Chowdhury ◽  
Shabana Shabbeer ◽  
Michael Carducci ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Valproic Acid ◽  
Cell Growth ◽  
Cancer Cell ◽  
Prostate Cancer Cell ◽  
Cancer Cell Growth

MiR-378 suppresses prostate cancer cell growth through downregulation of MAPK1 in vitro and in vivo

Tumor Biology ◽  
2015 ◽  
Vol 37 (2) ◽  
pp. 2095-2103 ◽  
Author(s):  
Qi-guang Chen ◽  
Wei Zhou ◽  
Tao Han ◽  
Shu-qi Du ◽  
Zhen-hua Li ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Growth ◽  
Cancer Cell ◽  
Prostate Cancer Cell ◽  
Cancer Cell Growth

scholarly journals Morphine Promotes Tumor Angiogenesis and Increases Breast Cancer Progression

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Sabrina Bimonte ◽  
Antonio Barbieri ◽  
Domenica Rea ◽  
Giuseppe Palma ◽  
Antonio Luciano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Growth ◽  
Mouse Model ◽  
Cancer Progression ◽  
Breast Cancer Progression ◽  
Cancer Cell Growth ◽  
Patients With Cancer ◽  
Human Breast Carcinoma Cells

Morphine is considered a highly potent analgesic agent used to relieve suffering of patients with cancer. Severalin vitroandin vivostudies showed that morphine also modulates angiogenesis and regulates tumour cell growth. Unfortunately, the results obtained by these studies are still contradictory. In order to better dissect the role of morphine in cancer cell growth and angiogenesis we performedin vitrostudies on ER-negative human breast carcinoma cells, MDA.MB231 andin vivostudies on heterotopic mouse model of human triple negative breast cancer, TNBC. We demonstrated that morphinein vitroenhanced the proliferation and inhibited the apoptosis of MDA.MB231 cells.In vivostudies performed on xenograft mouse model of TNBC revealed that tumours of mice treated with morphine were larger than those observed in other groups. Moreover, morphine was able to enhance the neoangiogenesis. Our data showed that morphine at clinical relevant doses promotes angiogenesis and increases breast cancer progression.

scholarly journals β-arrestin1-medieated inhibition of FOXO3a contributes to prostate cancer cell growth in vitro and in vivo

2018 ◽  
Vol 109 (6) ◽  
pp. 1834-1842 ◽  
Author(s):  
Zhenzhen Kong ◽  
Tuo Deng ◽  
Mengping Zhang ◽  
Zhijian Zhao ◽  
Yang Liu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Growth ◽  
Cancer Cell ◽  
Prostate Cancer Cell ◽  
Cancer Cell Growth

CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo

2014 ◽  
Vol 17 (6) ◽  
pp. 431-437 ◽  
Author(s):  
Y. Xiao ◽  
Y. Yuan ◽  
Y. Zhang ◽  
J. Li ◽  
Z. Liu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Growth ◽  
Cancer Cell ◽  
Cancer Cell Growth

Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo

The Prostate ◽  
1993 ◽  
Vol 22 (3) ◽  
pp. 225-233 ◽  
Author(s):  
Seema Garde ◽  
Anil Sheth ◽  
Arthur T. Porter ◽  
Kenneth J. Pienta
Keyword(s):  
Prostate Cancer ◽  
Cell Growth ◽  
Cancer Cell ◽  
Prostate Cancer Cell ◽  
Cancer Cell Growth

scholarly journals Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo

Molecules ◽  
2020 ◽  
Vol 25 (12) ◽  
pp. 2737
Author(s):  
Sariya Mapoung ◽  
Shugo Suzuki ◽  
Satoshi Fuji ◽  
Aya Naiki-Ito ◽  
Hiroyuki Kato ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Proliferation ◽  
Cancer Progression ◽  
Biological Activities ◽  
Xenograft Model ◽  
Castration Resistant Prostate Cancer ◽  
Curcumin Analog ◽  
Cycle Arrest

Curcumin (Cur) exhibits biological activities that support its candidacy for cancer treatment. However, there are limitations to its pharmacological effects, such as poor solubility and bioavailability. Notably, the use of Cur analogs has potential for addressing these limitations. Dehydrozingerone (DZG) is a representative of the half-chemical structure of Cur, and many reports have indicated that it is anticancer in vitro. We, therefore, have hypothesized that DZG could inhibit prostate cancer progression both in vitro and in vivo. Results revealed that DZG decreased cell proliferation of rat castration-resistant prostate cancer, PLS10 cells, via induction of the cell cycle arrest in the G1 phase in vitro. In the PLS10 xenograft model, DZG significantly decreased the growth of subcutaneous tumors when compared to the control via the inhibition of cell proliferation and angiogenesis. To prove that DZG could improve the limitations of Cur, an in vivo pharmacokinetic was determined. DZG was detected in the serum at higher concentrations and remained up to 3 h after intraperitoneal injections, which was longer than Cur. DZG also showed superior in vivo tissue distribution than Cur. The results suggest that DZG could be a candidate of the Cur analog that can potentially exert anticancer capabilities in vivo and thereby improve its bioavailability.

Sign in / Sign up

Export Citation Format

Share Document